Physician profile
Kevin D Webster
NPI 1861483638
$8,027.67
in general payments reported to CMS, 2019-2025
46 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $931 · 2020: $792 · 2021: $1,197 · 2022: $879 · 2023: $1,150 · 2024: $1,669 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,229.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,425.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $675.61 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $609.14 | 2019-2025 | |
| Abbvie INC. | $559.67 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $518.15 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $402.79 | 2019-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $386.19 | 2020-2025 | Rexulti |
| Astellas Pharma US INC | $380.48 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $363.16 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $349.21 | 2021-2025 | |
| Glaxosmithkline, LLC. | $348.63 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.49 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.11 | 2019-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $184.67 | 2024-2025 | Caplyta |
| Horizon Therapeutics Plc | $138.00 | 2020-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.